title: Evidence of heavy methylation in the galectin 3 promoter in early stages of prostate adenocarcinoma: development and validation of a methylated marker for early diagnosis of prostate cancer.
abstract: Galectins, soluble intracellular and extracellular beta-galactoside-binding proteins, are known to be involved in the progression and metastasis of various cancers, including prostate adenocarcinoma, but the detailed mechanism of their biological roles remains elusive. In the prostate cancer cell lines PC-3 and DU-145, galectin 3 (gal3) is present at normal levels, whereas in LNCaP, its expression is silenced. In LNCaP, the gal3 promoter was heavily methylated, whereas PC-3 or DU-145 cells showed negligible or no methylation in the gal3 promoter indicating a negative correlation between gal3 promoter methylation and its expression. On immunohistochemical analysis of normal and tumor prostate tissues, gal3 was found expressed both in nucleus and cytoplasm of benign prostatic hyperplasia, high-grade prostatic intraepithelial neoplasia, and stage I. The expression of the gal3 was found drastically downregulated in advanced stages and, interestingly, mostly in the cytoplasm. On methylation analysis, the gal3 promoter in stage II prostate adenocarcinoma (PCa) was found heavily methylated, whereas in stages III and IV, it was only lightly methylated. However, in stage I PCa, both heavy and light methylations were observed in the gal3 promoter. In normal and benign prostatic hyperplasia tissues, the gal3 promoter was almost unmethylated. The differential cytosine methylation in the gal3 promoter in stages I to IV PCa enabled us to develop and validate a methylation-specific polymerase chain reaction-based sensitive assay specific for stages I and II PCa. These stages are considered the critical stages for successful intervention, thus underscoring the significance of this diagnostic assay.
authors.affiliation: University of Maryland Biotechnology Institute, 701 E Pratt St, Baltimore, MD 21202, USA.
authors.forename: Hafiz
authors.initials: H
authors.lastname: Ahmed
authors.forename: Francesco
authors.initials: F
authors.lastname: Cappello
authors.forename: Vito
authors.initials: V
authors.lastname: Rodolico
authors.forename: Gerardo R
authors.initials: GR
authors.lastname: Vasta
references.citation: Cell Mol Life Sci. 2002 Feb;59(2):241-57
references.pmid: 11915942
references.citation: Expert Opin Ther Targets. 2007 Jan;11(1):81-90
references.pmid: 17150036
references.citation: Int J Cancer. 2000 Jul 20;89(4):361-7
references.pmid: 10956411
references.citation: J Natl Cancer Inst. 1998 Jul 1;90(13):1000-8
references.pmid: 9665149
references.citation: Am J Pathol. 1995 Sep;147(3):815-22
references.pmid: 7677193
references.citation: Am J Clin Pathol. 1999 May;111(5):623-31
references.pmid: 10230352
references.citation: Histol Histopathol. 2001 Jul;16(3):861-8
references.pmid: 11510978
references.citation: Gene Regul Syst Bio. 2007 Dec 11;1:313-25
references.pmid: 19936097
references.citation: Cancer Res. 2001 Jun 15;61(12):4820-6
references.pmid: 11406558
references.citation: Curr Opin Genet Dev. 1995 Jun;5(3):309-14
references.pmid: 7549424
references.citation: Clin Cancer Res. 2001 Sep;7(9):2727-30
references.pmid: 11555585
references.citation: Cancer Metastasis Rev. 2007 Dec;26(3-4):605-10
references.pmid: 17726578
references.citation: J Urol. 1994 Jun;151(6):1571-4
references.pmid: 7514690
references.citation: Nat Rev Genet. 2002 Jun;3(6):415-28
references.pmid: 12042769
references.citation: Int J Cancer. 1999 May 17;81(4):519-26
references.pmid: 10225438
references.citation: Cancer Metastasis Rev. 2007 Dec;26(3-4):567-78
references.pmid: 17786537
references.citation: Cancer. 1999 Dec 1;86(11):2353-63
references.pmid: 10590378
references.citation: J Mol Diagn. 2004 May;6(2):101-7
references.pmid: 15096565
references.citation: Clin Chem. 2008 May;54(5):874-82
references.pmid: 18339699
references.citation: Oncogene. 2004 Sep 30;23(45):7527-36
references.pmid: 15326483
references.citation: Oncogene. 2002 Aug 12;21(35):5400-13
references.pmid: 12154403
references.citation: Anticancer Agents Med Chem. 2008 Jan;8(1):22-36
references.pmid: 18220503
references.citation: Glycobiology. 2004 Mar;14(3):219-32
references.pmid: 14693912
references.citation: Curr Cancer Drug Targets. 2006 Sep;6(6):533-51
references.pmid: 17017872
references.citation: Cancer Treat Rev. 2002 Oct;28(5):255-71
references.pmid: 12435372
references.citation: Nat Rev Cancer. 2004 Feb;4(2):143-53
references.pmid: 14732866
references.citation: Cell Mol Life Sci. 2007 Jul;64(13):1679-700
references.pmid: 17497244
references.citation: Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1827-31
references.pmid: 1542678
references.citation: Glycoconj J. 2004;19(7-9):537-42
references.pmid: 14758077
references.citation: Front Biosci. 2007 May 01;12:3377-97
references.pmid: 17485307
references.citation: Scand J Immunol. 2007 Aug-Sep;66(2-3):143-58
references.pmid: 17635792
references.citation: Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7252-7
references.pmid: 8692978
references.citation: Clin Cancer Res. 2004 Dec 15;10(24):8472-8
references.pmid: 15623627
references.citation: Arch Biochem Biophys. 1998 Jan 1;349(1):7-20
references.pmid: 9439577
references.citation: Clin Chem. 2000 Aug;46(8 Pt 1):1078-84
references.pmid: 10926886
references.citation: Urology. 2007 Apr;69(4):714-20
references.pmid: 17445657
references.citation: Clin Chim Acta. 2001 Nov;313(1-2):143-6
references.pmid: 11694252
references.citation: Cancer Res. 2004 Jul 1;64(13):4442-52
references.pmid: 15231653
references.citation: J Clin Oncol. 2005 Sep 20;23(27):6569-75
references.pmid: 16170165
references.citation: Prostate. 2000 Jul 1;44(2):118-23
references.pmid: 10881021
references.citation: Cell. 2000 Jan 7;100(1):57-70
references.pmid: 10647931
references.citation: Expert Rev Mol Diagn. 2004 Jul;4(4):513-26
references.pmid: 15225099
references.citation: Cancer Res. 1999 Dec 15;59(24):6239-45
references.pmid: 10626818
references.citation: Clin Cancer Res. 2004 Aug 15;10(16):5518-22
references.pmid: 15328191
references.citation: Int J Cancer. 1994 Feb 15;56(4):474-80
references.pmid: 8112883
references.citation: Cancer Res. 2000 Nov 1;60(21):5941-5
references.pmid: 11085508
references.citation: Biochem Biophys Res Commun. 2007 Jun 22;358(1):241-6
references.pmid: 17481580
references.citation: Urol Res. 1999 Oct;27(5):362-7
references.pmid: 10550525